Search results
Added:
6 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Added:
6 months ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation…
View more
Added:
4 months ago
Explore the diagnostic and therapeutic complexities of cardiac sarcoidosis with Prof Emer Joyce.This presentation, part of the comprehensive Cardiomyopathies track, tackles the persistent challenges in cardiac sarcoidosis, emphasizing that despite decades of clinical experience, diagnosis remains the field's greatest hurdle.Prof Joyce explores the heterogeneous clinical phenotypes capable of…
View more
Added:
1 year ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more
Added:
1 year ago
AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care.Trials covered in detail…
View more
Added:
1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism…
View more
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What…
View more
Added:
7 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Dr Patricia Campbell and Prof Paul Kalra share their expert perspectives on the use of IV iron in clinical practice.
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core…
View more